# France Brucellosis Market

> France Brucellosis Market Research Report: Size, Share, Trend Analysis By Species (Brucella suis, Brucella abortus, Brucella melitensis, Brucella canis, others), By End-User (hospitals & diagnostic centers, academic institutes, pharmaceutical & biotechnology companies, others), By Diagnosis (serological tests, molecular techniques, bone marrow biopsy, X-rays, computerized tomography (CT), magnetic resonance imaging (MRI), cerebrospinal fluid culture, echocardiography, others), By Treatment (antibiotics, vaccines, others), By Region - Forecast to 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.28%
- **2024:** $ 29.59 Million
- **2025:** $ 31.98 Million
- **2035:** $ 57.83 Million
- **Key Players:** Zoetis (US), Merck Animal Health (US), Boehringer Ingelheim (DE), Cegelec (FR), Virbac (FR), Heska Corporation (US), IDT Biologika (DE), Vetoquinol (FR)

**Report ID:** MRFR/LS/51831-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/france-brucellosis-market-53592

---

## Market Summary

## **France Brucellosis Market Overview**

As per MRFR analysis, the France Brucellosis Market Size was estimated at 8.54 (USD Million) in 2023.The France Brucellosis Market is expected to grow from 9.3(USD Million) in 2024 to 27.9 (USD Million) by 2035. The France Brucellosis Market CAGR (growth rate) is expected to be around 10.503% during the forecast period (2025 - 2035).

**Key France Brucellosis Market Trends Highlighted**

The market for brucellosis in France is undergoing a number of noteworthy trends that are being fueled by both regulatory actions and public health concerns. The growing awareness of zoonotic diseases, particularly brucellosis, which affects cattle and can be spread to people, is one of the main factors propelling the market.

Stricter monitoring and vaccination campaigns are the result of the French government's aggressive efforts to prevent and eradicate brucellosis, especially in cattle and sheep. A greater understanding of the public health hazards posed by brucellosis outbreaks, which can have a serious effect on both human and animal populations, is reflected in this proactive approach.

Possibilities in France The market for brucellosis includes developments in vaccination and diagnostic technology as well as the possibility of more funding for research projects. Research institutes, veterinary groups, and government organizations working together can promote innovation in brucellosis prevention and treatment, opening the door to better management approaches.

Furthermore, there is potential for creating educational initiatives aimed at farmers and veterinarians to raise knowledge of early identification and preventive actions as the industry develops. Additionally, recent patterns show a move toward more integrated methods to brucellosis management, combining community involvement, public health tactics, and animal health management.

Sustainable farming methods that support animal welfare and successfully control disease risks are the main emphasis of the French agricultural industry. This comprehensive approach paves the path for a coordinated response to brucellosis and is in line with larger European Union goals pertaining to food safety and animal disease prevention.

In light of these developments, it is clear how important it is for France to work together to address the problems caused by brucellosis in order to eventually eradicate and better control the illness.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**France Brucellosis Market Drivers**

**Increasing Awareness and Testing for Brucellosis**

An increasing focus on public health in France has led to greater awareness of zoonotic diseases such as Brucellosis. The French government has implemented various public health campaigns aimed at educating the population about the transmission and prevention of Brucellosis, particularly among livestock.

The French Ministry of Agriculture reported that in recent years, the incidence of Brucellosis in livestock has significantly decreased, thanks to national surveillance initiatives. This increased awareness has also led to a surge in diagnostic testing for Brucellosis, which is expected to continue fuelling growth in the France [Brucellosis Market](../../../reports/brucellosis-market-5159).

The overall rise in the number of livestock being tested is reflected in a 30% increase in laboratory testing conducted over the last four years, suggesting an ongoing commitment to controlling the disease.

**Technological Advancements in Diagnostics**

The development of novel diagnostic technologies plays a crucial role in the France Brucellosis Market. New methods such as molecular diagnostic techniques and rapid test kits have been gaining traction.

French biotechnology companies, such as bioMérieux, have pioneered innovative solutions that provide accurate results much quicker than traditional methods. The rapid testing and improved accuracy directly increase disease control and monitoring.

The heightened accuracy and speed of new testing kits have been shown to reduce turnaround times by over 50%, enhancing the overall efficiency of Brucellosis diagnostics. As a result, more livestock producers are likely to adopt these advanced diagnostic tools, promoting market growth.

**Government Policies and Regulations**

Government policies surrounding animal health and disease control in France significantly influence the Brucellosis Market. The French government, along with the European Union guidelines, has established stringent regulations aimed at minimizing the risk of Brucellosis outbreaks in both livestock and humans.

These policies have fostered an environment where agricultural producers are more inclined to invest in prevention and control measures, including vaccination programs.

Government initiatives have successfully reduced Brucellosis cases in livestock by approximately 40% since the introduction of vaccination mandates and health protocols. As such, these health regulations not only encourage producers to maintain compliance but also stimulate growth within the market as the need for related products and services proliferates.

**France Brucellosis Market Segment Insights**

**Brucellosis Market species Insights**

The France Brucellosis Market is significantly influenced by various species of Brucella, each playing a critical role in the dynamics of the market. Brucella suis is known for its impact on swine, which is a vital part of France's agricultural landscape, contributing to the country's meat production industry.

The presence of B. suis poses a challenge for livestock health, impacting the supply chain and food safety concerns related to pork products. Meanwhile, B. abortus primarily affects cattle, which are fundamental to France’s dairy and beef industries.

The management and control of this species are essential to sustain the economic stability and growth of these sectors. Furthermore, B. melitensis is often associated with sheep and goats, contributing to the dairy market, especially in regions where these livestock products are prominent.

The prevalence of this species highlights the need for adequate veterinary services and biosecurity measures in agricultural practices. Overall, the significance of these Brucella species in the France Brucellosis Market is underscored by their influence on livestock health, public health implications, and the associated economic factors within the agriculture industry.

Addressing challenges posed by these species through effective monitoring and control strategies represents a critical opportunity for market stakeholders in the region, fostering advancements in veterinary practices and wildlife management.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**France Brucellosis Market Key Players and Competitive Insights**

The France Brucellosis Market is characterized by a dynamic and competitive landscape, driven by factors such as the increasing incidence of brucellosis among livestock, the growing awareness of animal health among farmers, and stringent government regulations aimed at disease control.

This market comprises various players offering vaccines, diagnostic kits, and treatments specifically designed to tackle brucellosis in cattle, sheep, and goats.

Competitive dynamics are influenced by ongoing research and development activities, partnerships for product innovation, and the need for effective disease management solutions. Players in the market are focusing on enhancing product efficacy and developing new technologies to stay ahead in this niche field.

Intervet plays a crucial role in the France Brucellosis Market, offering a variety of vaccines and diagnostic solutions tailored for the prevention and management of brucellosis in livestock. The company is known for its strong reputation and commitment to research and development, which enables it to provide innovative products that address the specific needs of farmers in France.

Intervet's established network of distribution channels ensures its products are readily available to veterinary practitioners and livestock producers across the region. Moreover, the company is recognized for its collaboration with local agricultural organizations, which enhances its presence and strengthens its market position.

Intervet's focus on high-quality products and customer education further underpins its competitive edge, as it works to effectively influence the management of health within the livestock sector.

IDEXX Laboratories holds a prominent position within the France Brucellosis Market, recognized for its extensive portfolio of diagnostic tests and services aimed at early detection and management of brucellosis.

The company offers key products that facilitate accurate and timely diagnosis, allowing veterinarians to implement effective treatment plans. IDEXX Laboratories’ strong market presence is bolstered by its commitment to research in veterinary diagnostics, which has led to innovative solutions that cater specifically to the needs of the French livestock industry.

Their focus on maintaining high standards of quality and reliability in testing contributes to their solid reputation among veterinarians and livestock managers.

IDEXX Laboratories has also pursued strategic partnerships and acquisitions to enhance its capabilities, resulting in a broader range of services available to its customers in France, thus solidifying its competitive advantage in this critical sector of animal health.

**Key Companies in the France Brucellosis Market Include:**

- Intervet
- IDEXX Laboratories
- Boehringer Ingelheim Vetmedica
- Diamond Animal Health
- Vetoquinol
- Neogen Corporation
- Heska Corporation
- Merck Animal Health
- AgriLabs
- Boehringer Ingelheim
- Ceva Santé Animale
- Virbac
- Elanco Animal Health
- Phibro Animal Health
- Zoetis

**France Brucellosis****Market****Developments**

In recent developments, the France Brucellosis Market has seen heightened activity, particularly with companies such as Intervet, IDEXX Laboratories, and Boehringer Ingelheim Vetmedica focusing on enhancing their veterinary solutions to combat brucellosis.

As of August 2023, France has reported an increase in brucellosis cases in livestock, prompting government agencies to reinforce vaccination and monitoring programs. This rise in disease incidence has resulted in a push for innovations in diagnostics and treatments, namely by firms such as Merck Animal Health and Zoetis, which are investing in Research and Development to develop more effective vaccines and diagnostic kits.

Moreover, recent acquisitions have also shaped the landscape, with Boehringer Ingelheim announcing in July 2023 a strategic acquisition aimed at boosting their portfolio in animal health specifically targeting infectious diseases including brucellosis.

The market has seen significant growth, with companies like Elanco Animal Health and Virbac expanding their operations in France to cater to the increasing demand for brucellosis management solutions.

Over the last two to three years, the market has consistently responded to epidemiological trends, adjusting product offerings and improving surveillance mechanisms, indicating a proactive approach by major players in the France Brucellosis Market.

**France Brucellosis Market Segmentation Insights**

**Brucellosis Market species Outlook**

- Brucella suis
- B. abortus
- B. melitensis

## Market Drivers

### Rising Awareness Among Farmers

There is a growing awareness among farmers regarding the implications of [brucellosis](https://www.marketresearchfuture.com/reports/brucellosis-market-5159) on livestock health and productivity, which is positively impacting the France brucellosis market. Educational initiatives and outreach programs conducted by agricultural organizations have played a pivotal role in informing farmers about the risks associated with brucellosis and the importance of vaccination and biosecurity measures. As of 2025, surveys indicate that over 70% of farmers in France are now aware of the disease and its prevention strategies. This heightened awareness is likely to lead to increased adoption of vaccination programs and improved herd management practices, ultimately contributing to a decline in brucellosis incidence. Consequently, the France brucellosis market stands to benefit from this shift in farmer attitudes and practices.

### Regulatory Framework and Compliance

The France brucellosis market is significantly influenced by stringent regulatory frameworks aimed at controlling and preventing the disease. The French government, through its Ministry of Agriculture and Food, has established comprehensive guidelines for livestock management and disease reporting. These regulations mandate regular testing and vaccination of cattle, which is crucial in maintaining herd health and preventing outbreaks. The enforcement of these regulations not only ensures public health safety but also supports the economic stability of the livestock sector. In 2025, the French government allocated substantial resources to enhance disease surveillance and control measures, reflecting a commitment to eradicating brucellosis. This proactive approach is likely to bolster the France brucellosis market by fostering a safer environment for livestock production and trade.

### Advancements in Diagnostic Technologies

Technological advancements in diagnostic methods are reshaping the France brucellosis market. The introduction of rapid and accurate diagnostic tests has improved the ability to detect brucellosis in livestock, facilitating timely interventions. For instance, the use of polymerase chain reaction (PCR) tests has gained traction, allowing for quicker identification of infected animals. This is particularly relevant in France, where the livestock sector is a vital component of the economy. In 2025, the market for diagnostic tools is projected to grow by approximately 15%, driven by the increasing demand for efficient disease management solutions. Enhanced diagnostic capabilities not only aid in controlling brucellosis outbreaks but also contribute to the overall health of the livestock population, thereby supporting the France brucellosis market.

### Consumer Preferences for Quality Assurance

The France brucellosis market is also shaped by evolving consumer preferences for quality assurance in food products. As consumers become more health-conscious, there is a rising demand for meat and dairy products that are certified free from brucellosis. This trend is prompting producers to adopt stringent quality control measures and participate in certification programs that guarantee the safety of their products. In 2025, it is estimated that the market for certified brucellosis-free products will expand by 20%, reflecting the increasing consumer demand for transparency and safety in food sourcing. This shift not only enhances consumer trust but also encourages producers to invest in better health management practices, thereby positively influencing the France brucellosis market.

### International Trade and Export Opportunities

The France brucellosis market is significantly impacted by international trade dynamics and export opportunities. France, being a key player in the European livestock market, faces pressure to maintain high health standards to access international markets. Countries importing French livestock products often require proof of brucellosis-free status, which compels producers to adhere to rigorous health protocols. In 2025, the export of French livestock products is projected to increase by 10%, driven by the demand for high-quality, disease-free products in global markets. This trend not only enhances the competitiveness of French livestock on the international stage but also reinforces the importance of effective brucellosis control measures within the France brucellosis market.

## Future Outlook

The France brucellosis market is projected to grow at a 6.28% CAGR from 2025 to 2035, driven by advancements in [veterinary diagnostics](https://www.marketresearchfuture.com/reports/veterinary-diagnostics-market-21729) and increased awareness of zoonotic diseases.

**New opportunities:**

- Development of mobile diagnostic units for rapid brucellosis testing in rural areas.
- Investment in [vaccine research](https://www.marketresearchfuture.com/reports/vaccine-research-market-27935) to enhance livestock immunity against brucellosis.
- Partnerships with agricultural cooperatives to promote disease prevention programs.

By 2035, the market is expected to be robust, driven by innovation and strategic partnerships.

## Segment Insights

### By Species: Brucella melitensis (Largest) vs. Brucella abortus (Fastest-Growing)

The market share distribution within the brucellosis species segment shows that Brucella melitensis holds the largest portion, primarily due to its prevalence in livestock and its significant impact on public health. Following closely is Brucella abortus, which is recognized for its growing incidence in cattle populations. Other species like Brucella suis and Brucella canis contribute to the market but do not significantly challenge the dominance of these two main species.

The growth trends in this segment are influenced by factors such as increasing awareness of zoonotic diseases and stricter veterinary regulations. The demand for effective vaccination programs and control measures is pushing Brucella abortus to become the fastest-growing segment as veterinarians and farmers strive to mitigate brucellosis outbreaks. Moreover, advancements in diagnostic technologies are aiding in better detection, which helps in managing disease spread effectively.

Brucella melitensis (Dominant) vs. Brucella abortus (Emerging)

Brucella melitensis, as the dominant segment, is predominantly found in sheep and goats, leading to its significant share in the France brucellosis market due to its association with severe health issues in both animals and humans. Its prevalence demands continuous monitoring and control measures, emphasizing its impact on livestock health. In contrast, Brucella abortus, emerging as a key player, primarily affects cattle, and is rapidly gaining attention due to rising infection rates among cattle herds. The increasing incidence of brucellosis in livestock and rising veterinary interventions are driving Brucella abortus towards becoming a crucial species for market dynamics, making it a focal point for both veterinary health and agricultural stakeholders.

### By Diagnosis: Serological Tests (Largest) vs. Molecular Techniques (Fastest-Growing)

In the France brucellosis market, serological tests dominate the Diagnosis segment, holding a substantial market share compared to other testing methods. Molecular techniques are emerging rapidly, gaining traction due to their accuracy and speed in diagnosing brucellosis. Bone marrow biopsy, X-rays, and other imaging techniques also contribute but to a lesser extent, with serological tests leading the way and setting the standard for initial diagnosis.

The growth trends in the Diagnosis segment are driven by advancements in laboratory technologies and the increasing need for accurate and timely diagnosis of brucellosis. The rising prevalence of zoonotic diseases and the focus on enhancing public health initiatives further propel the demand for molecular techniques. This shift toward faster, more reliable testing methods illustrates the overall trend toward innovation in disease diagnosis within this market.

Serological Tests (Dominant) vs. Molecular Techniques (Emerging)

Serological tests remain the dominant choice in the Diagnosis segment due to their widespread availability and established methodologies that provide reliable results in diagnosing brucellosis. These tests are crucial for preliminary screening and contribute significantly to monitoring and controlling outbreaks. In contrast, molecular techniques are emerging with the potential to transform diagnostic approaches. They offer higher sensitivity and specificity, significantly reducing time to diagnosis. As healthcare providers in the France brucellosis market prioritize innovation, molecular techniques are expected to see rapid adoption, complementing the traditional serological tests and catering to the evolving needs of the healthcare sector.

### By Treatment: Antibiotics (Largest) vs. Vaccines (Fastest-Growing)

In the France brucellosis market, antibiotics constitute the largest segment, holding a substantial share of the treatment options available. This segment benefits from well-established usage and a robust supply chain, making it a go-to choice for veterinary practitioners addressing brucellosis in livestock. Conversely, vaccines represent the fastest-growing segment, driven by increasing awareness of preventive measures and the rising demand for sustainable animal health strategies. 

Growth in the treatment segment is largely propelled by advances in vaccine technology and the increasing prevalence of brucellosis outbreaks. Antibiotics will continue to see reliance due to traditional treatment success. Meanwhile, vaccines are becoming more appealing, as regulations increasingly favor preventive over reactive measures, encouraging investment and development in this area.

Antibiotics (Dominant) vs. Vaccines (Emerging)

Antibiotics in the France brucellosis market are recognized as the dominant force in treatment, demonstrating proven efficacy against brucellosis infections in livestock. Their established role reinforces their position as the preferred option for veterinarians and farmers when managing outbreaks. In contrast, vaccines, though currently an emerging segment, are quickly gaining traction due to their potential to prevent disease before it occurs. Enhanced research and development, coupled with government initiatives promoting vaccination, support the transition from reliance on antibiotics to more sustainable practices. This shift reflects growing veterinary and consumer trends that prioritize both animal welfare and public health, paving the way for an evolving landscape in disease management.

### By End-User: Hospitals & Diagnostic Centers (Largest) vs. Academic Institutes (Fastest-Growing)

In the France brucellosis market, hospitals and diagnostic centers hold the largest share, benefiting from their pivotal role in the diagnosis and treatment of brucellosis. This segment is primarily driven by the increasing prevalence of infectious diseases and the need for specialized diagnostic testing. Academic institutes also play a critical role, fostering research and development, which is essential for advancements in diagnostics and therapeutics. They are becoming increasingly important as research locales, particularly focusing on brucellosis, thus capturing a growing share of the market.

The growth trends in the France brucellosis market indicate a significant shift towards increased investment in academic research and diagnostics. Hospitals and diagnostic centers are expanding their capabilities to meet rising demands, while academic institutes are securing more funding and resources for innovative research. The collaboration between these segments is enhancing diagnostic accuracy and treatment outcomes, driving the overall market growth. Furthermore, the emphasis on public health initiatives is catalyzing a surge in awareness and testing, solidifying the positions of these segments in the market.

Hospitals & Diagnostic Centers (Dominant) vs. Academic Institutes (Emerging)

Hospitals and diagnostic centers in the France brucellosis market are recognized as the dominant players due to their established infrastructure and expertise in handling infectious diseases. They provide essential diagnostic services and contribute to the treatment landscape, ensuring the management of brucellosis is efficient and effective. Alternatively, academic institutes represent the emerging force, contributing to the market through research and innovation. These institutes foster collaboration with healthcare providers and biopharmaceutical firms, focusing on novel diagnostics and therapeutic solutions. Their growing involvement is critical for addressing the knowledge gaps in brucellosis, ultimately enhancing public health response strategies.

## Competitive Benchmarking

The competitive dynamics within the brucellosis market in France are characterized by a blend of innovation, strategic partnerships, and a focus on regional expansion. Key players such as Zoetis (US), Merck Animal Health (US), and Boehringer Ingelheim (DE) are actively shaping the landscape through their operational strategies. For instance, Zoetis (US) has been emphasizing digital transformation and the integration of advanced technologies into its product offerings, which appears to enhance its market position. Meanwhile, Merck Animal Health (US) is focusing on strategic partnerships to bolster its research and development capabilities, thereby fostering innovation in vaccine development. Boehringer Ingelheim (DE) is also pursuing a strategy of regional expansion, particularly in underserved markets, which may provide it with a competitive edge in the long term.

The business tactics employed by these companies include localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The market structure is moderately fragmented, with several players vying for market share. However, the collective influence of these key players is significant, as they drive advancements in product development and distribution strategies, thereby shaping the overall competitive environment.

In December 2025, Zoetis (US) announced the launch of a new [brucellosis vaccine](https://www.marketresearchfuture.com/reports/brucellosis-vaccine-market-43217) that utilizes cutting-edge mRNA technology. This strategic move is likely to position the company at the forefront of innovation in the market, potentially leading to increased adoption rates among livestock producers. The introduction of this vaccine may not only enhance animal health but also contribute to the reduction of brucellosis incidence in cattle, aligning with public health objectives.

In November 2025, Merck Animal Health (US) entered into a collaborative agreement with a French biotechnology firm to develop a novel diagnostic tool for brucellosis. This partnership is indicative of Merck's commitment to enhancing its product portfolio through innovative solutions. The strategic importance of this collaboration lies in its potential to improve early detection and management of brucellosis, which could significantly impact disease control efforts in livestock.

In October 2025, Boehringer Ingelheim (DE) expanded its distribution network in France by partnering with local veterinary clinics. This strategic action is expected to enhance the accessibility of its brucellosis vaccines and treatments, thereby increasing market penetration. By strengthening its distribution channels, Boehringer Ingelheim may improve its competitive positioning and responsiveness to customer needs.

As of January 2026, current trends in the brucellosis market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in product development and diagnostics. Strategic alliances among key players are shaping the competitive landscape, fostering innovation and enhancing supply chain reliability. The shift from price-based competition to a focus on technological advancements and sustainable practices is becoming evident. Moving forward, competitive differentiation is likely to evolve, with companies prioritizing innovation and reliability over traditional pricing strategies.

## Recent News & Developments

In recent developments, the France Brucellosis Market has seen heightened activity, particularly with companies such as Intervet, IDEXX Laboratories, and Boehringer Ingelheim Vetmedica focusing on enhancing their veterinary solutions to combat brucellosis.

As of August 2023, France has reported an increase in brucellosis cases in livestock, prompting government agencies to reinforce vaccination and monitoring programs. This rise in disease incidence has resulted in a push for innovations in diagnostics and treatments, namely by firms such as Merck Animal Health and Zoetis, which are investing in Research and Development to develop more effective vaccines and diagnostic kits.

Moreover, recent acquisitions have also shaped the landscape, with Boehringer Ingelheim announcing in July 2023 a strategic acquisition aimed at boosting their portfolio in animal health specifically targeting infectious diseases including brucellosis.

The market has seen significant growth, with companies like Elanco Animal Health and Virbac expanding their operations in France to cater to the increasing demand for brucellosis management solutions.

Over the last two to three years, the market has consistently responded to epidemiological trends, adjusting product offerings and improving surveillance mechanisms, indicating a proactive approach by major players in the France Brucellosis Market.

## Report Scope

| MARKET SIZE 2024 | 29.59(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 31.98(USD Million) |
| MARKET SIZE 2035 | 57.83(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.28% (2024 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Zoetis (US), Merck Animal Health (US), Boehringer Ingelheim (DE), Cegelec (FR), Virbac (FR), Heska Corporation (US), IDT Biologika (DE), Vetoquinol (FR) |
| Segments Covered | Application, End Use, Testing Method, Disease Type |
| Key Market Opportunities | Emerging diagnostic technologies enhance early detection and management of brucellosis in the France brucellosis market. |
| Key Market Dynamics | Regulatory changes and heightened surveillance are reshaping the France brucellosis market landscape and competitive dynamics. |
| Countries Covered | France |

## Frequently Asked Questions

**Q: What is the current valuation of the France brucellosis market in 2024?**
A: The overall market valuation was $19.73 Million in 2024.

**Q: What is the projected market valuation for the France brucellosis market by 2035?**
A: The projected valuation for 2035 is $43.14 Million.

**Q: What is the expected CAGR for the France brucellosis market during the forecast period 2025 - 2035?**
A: The expected CAGR for the market during this period is 7.37%.

**Q: Which companies are the key players in the France brucellosis market?**
A: Key players include Zoetis Inc, Merck & Co Inc, Boehringer Ingelheim, Ceva Santé Animale, Virbac, Heska Corporation, Vetoquinol SA, and Phibro Animal Health Corporation.

**Q: What are the main segments of the France brucellosis market?**
A: The main segments include Species, Diagnosis, Treatment, and End-User.

**Q: What was the market value for Brucella melitensis in 2024?**
A: The market value for Brucella melitensis was $5.0 Million in 2024.

**Q: How much is the market for antibiotics projected to grow by 2035?**
A: The market for antibiotics is projected to grow from $5.93 Million in 2024 to $13.12 Million by 2035.

**Q: What is the market value for serological tests in 2024?**
A: The market value for serological tests was $3.5 Million in 2024.

**Q: What is the projected market value for hospitals & diagnostic centers by 2035?**
A: The projected market value for hospitals & diagnostic centers is $13.12 Million by 2035.

**Q: What was the market value for Brucella canis in 2024?**
A: The market value for Brucella canis was $2.5 Million in 2024.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/france-brucellosis-market-53592*